PET (Positron Emission Tomography) is a nuclear medicine imaging modality used to visualize the structures within the human body. In most cases, a PET scan is performed in conjunction with a computed tomography (CT) scan, a process known as hybrid imaging.
Consequently, these noninvasive imaging procedures are rapid and sensitive to anatomical and biological changes in the body and provide essential information about how a particular disease behaves in patients, for example, in staging, restaging, and assessing cancer treatment response.
During the PET imaging procedure, the patient is injected with a low radiopharmaceutical (radiotracer) dose such as 18FDG, Na18F, 68Ga-PSMA and 68Ga-DOTATATE. However, conventional CT and MRI (magnetic resonance imaging) use X-rays to obtain 3D anatomical images. An injected radiation dose into the human body distributes to specific areas distributed close metabolism when using 18FDG to identify absorptivity used in the body.
PET imaging also enables the determination of a tumour’s metabolism rate to see if it is still active. A further hybrid uses PET and MRI to facilitate improvement in the visualisation of specific structures, for example, in the brain and pelvic organs.
In another situation regarding lung cancer diagnosis, it is paramount for the oncologist to determine if the patient requires curative surgery and chemotherapy or only palliative chemotherapy. Therefore, to enable this decision, using 18FDG radiotracer in a PET-CT scan will allow the oncologist to verify if the lung cancer has spread to a particular lymph node.
The essence of PET imaging is to evaluate metabolic changes that precede anatomical changes, which MRI observes. Consequently, positron emission tomography imaging detects tumours early and assesses dementia and seizures. It also observes the functions of the heart and evaluates inflammatory diseases.
You are here:
home »
Radionuclide Therapy Effects include potential organ toxicity, requiring careful monitoring to manage patient outcomes effectively.
Radionuclide Therapy Effects Uncovered: The Hidden Impact on Our Organs Read Post »
FLYRCADO is an innovative radiopharmaceutical agent specifically designed for use in Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI). It
FLYRCADO in Positron Emission Tomography (PET) Myocardial Perfusion Imaging Read Post »
The regulations in 21 CFR Part 212 ensure PET drugs are manufactured under strict quality control and safety standards.
Ensuring Quality and Compliance: A Guide to 21 CFR Part 212 for PET Drug Manufacturing Read Post »
Pittsburgh Compound-B allows researchers to visualise amyloid plaques in the brain, aiding in Alzheimer’s disease diagnosis and study.
Advancements in Carbon-11 synthesis technology have significantly improved the efficiency and accuracy of PET imaging in medical diagnostics.
The Synthesis and Applications of Carbon-11 in Modern Nuclear Medicine Read Post »
Medical physics combines physics principles with medical science to enhance diagnostics and treatment, improving global healthcare outcomes significantly.
The gamma camera allows non-invasive imaging, enabling detailed diagnosis and monitoring of various medical conditions with precision.
The Role of the Medical Gamma Camera in Modern Healthcare Read Post »
Nuclear chemistry provides critical insights into energy production, medical advancements, and environmental protection, shaping a sustainable future.
Exploring Nuclear Chemistry: Innovations, Applications, and Future Prospects Read Post »
Positrons, the antimatter counterparts of electrons, are crucial in physics, enabling advances in PET scans and material science.
Understanding Positrons: Characteristics, Discovery, and Applications Read Post »
Positron Emission Tomography Imaging has advanced with cutting-edge technologies, enhancing diagnostic accuracy and expanding clinical applications dramatically.
Breakthroughs in Positron Emission Tomography Imaging Read Post »
Nuclear medicine and the future of precise, personalised care in diagnosing and treating diseases.
Nuclear Medicine at the Centre of Radiology and Radiopharmaceuticals Read Post »
Proton beam therapy targets cancer accurately, minimising side effects but faces challenges in cost and accessibility.
Proton Beam Therapy: A New Horizon in Precision Oncology Read Post »
Exploring the evolving role of radiopharmaceutical diagnostics in enhancing disease detection and personalising treatment in modern medicine.
Radiopharmaceutical Diagnostics and Imaging Technologies Read Post »
Radiotheranostics merges diagnostics and therapy, offering targeted cancer treatment amidst challenges like high costs and need for specialised facilities.
Revolutionising Cancer Care: The Promise and Challenges of Radiotheranostics Read Post »
PET imaging dramatically enhances early disease detection, significantly improving patient outcomes in various medical fields.
PET Imaging and Its Transformative Impact in Modern Medicine Read Post »
Gallium-68 and Lutetium-177 labelled Girentuximab mark a breakthrough in diagnosing and treating hepatocellular carcinoma.
Targeting Hepatocellular Carcinoma: The Emerging Role of Girentuximab Read Post »
Folate Receptor Targeting Agents revolutionise cancer diagnosis and treatment with Fluorine-18 and Rhenium-188 labelling.
Folate Receptor Targeting Agents: Pioneering Progress in Cancer Diagnosis and Therapy Read Post »
Somatostatin Receptor Targeting Agents offer groundbreaking diagnostic and therapeutic solutions for neuroendocrine tumour management and care.
Somatostatin Receptor Targeting Agents: Revolutionising Neuroendocrine Tumour Management Read Post »
PSMA targeting agents revolutionise prostate cancer care with precise diagnostics and targeted therapeutic approaches.
225Ac-PSMA-617 revolutionises prostate cancer treatment, offering targeted, effective therapy with promising clinical trial results.
Actinium-225 PSMA-617: Revolutionising Prostate Cancer Treatment Read Post »
Radiopharmaceuticals, combining radioactive and pharmaceutical elements, enable precise diagnosis and treatment in nuclear medicine.
The Transformative Impact of Radiopharmaceuticals in Medical Imaging Read Post »
Nuclear medicine has transformed healthcare over a century, innovating in diagnostics and treatments significantly.
History of Nuclear Medicine: A Century of Innovation and Impact Read Post »
Zirconium radiopharmaceuticals enhance nuclear medicine with precise diagnostics and potential therapeutic applications.
Zirconium Radiopharmaceuticals in Nuclear Medicine Read Post »
In Brazil, the growing radiopharmaceutical market, driven by chronic disease and advanced imaging technologies, is becoming increasingly significant in healthcare.
Advancing Healthcare: The Dynamic Growth of Brazil’s Radiopharmaceutical Market Read Post »
Copper radiopharmaceuticals offer groundbreaking diagnostic and therapeutic applications, revolutionising nuclear medicine, particularly in oncology and cardiology.
Exploring Copper Radiopharmaceuticals: Innovations and Applications in Nuclear Medicine Read Post »
[18F]flurpiridaz PET shows superior sensitivity and lower radiation in detecting coronary artery disease compared to SPECT.
[F-18]NAV-4694 shows promise in Alzheimer’s detection, with a strong safety profile and clear regulatory pathways.
Immuno-PET merges monoclonal antibodies with PET imaging, transforming precision oncology through enhanced tumor detection and monitoring.
Immuno-PET: Cancer Detection and Treatment in Nuclear Medicine Read Post »
Whole-body PET imaging transformed medical research, enabling personalised medicine and impacting diagnostics, therapy, and science.
Pancreatic cancer demands accurate prognosis, improved treatment strategies, and PET radiomic analysis for optimised post-resection outcomes.
Prognostic Accuracy in Resected Pancreatic Cancer: Using Radiomic PET Imaging Read Post »
Medical imaging advancements, aided by deep learning reconstruction, enhance diagnosis accuracy and efficiency, overcoming traditional limitations.
Fluorine-18 Sodium Fluoride (18F-NaF) is an effective, safe diagnostic radiopharmaceutical, revolutionising bone imaging and detecting skeletal abnormalities with high accuracy.
Fluorine-18 Sodium Fluoride: Applications and Advantages Read Post »
Fluorine-18 Flucicovine (Axumin) improves prostate cancer detection, enabling accurate diagnosis and targeted treatments with PET imaging.
Fluorine-18 Flortaucipir: selective tau-binding radiotracer, Alzheimer’s diagnosis, PET imaging, regional limitations, off-target binding, combined diagnostic approach.
Fluorine-18 Flortaucipir: A Novel Diagnostic Tool for Alzheimer’s Disease Read Post »
Copper-64 DOTATE, a diagnostic radiopharmaceutical, effectively targets neuroendocrine tumours, enabling precise imaging and personalised treatment plans for cancer patients.
Carbon-14 Choline, a radioactive isotope, improves medical imaging accuracy and expands molecular research, aiding cancer diagnosis and treatment.
Carbon-11 Choline: A Radiopharmaceutical with Expanding Applications Read Post »
PET imaging is used in oncology, neurology and cardiology.
Molecular Imaging Technology: Use of PET in Clinical Microdose Studies Read Post »
PET probes to investigate the movement of nucleosides across biological membranes.
Hydantoin is found in pharmacologically active molecules, such as phenytoin.
Synthesis, NMR analysis and applications of isotope-labelled hydantoins Read Post »
PET imaging (Positron Emission Tomography) is an established diagnostic imaging tool used in Nuclear Medicine.
PET-CT and PET-MRI in Radiation Therapy Planning Read Post »
Overview on the central role of chelation in labelling radiocompounds.
Basic premises to molecular imaging and radionuclide therapy Read Post »
Topics on PET imaging, automated radiosynthesis, breast cancer, prostate cancer therapy and ultrasound.
Inaugural editorial review: nuclear medicine, diagnostic imaging and therapy Read Post »
